- Home
- ATAI vs CABA Comparison
ATAI vs CABA Comparison
Compare ATAI & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- CABA
- Stock Information
- Founded
- ATAI 2018
- CABA 2017
- Country
- ATAI Germany
- CABA United States
- Employees
- ATAI N/A
- CABA N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATAI Health Care
- CABA Health Care
- Exchange
- ATAI Nasdaq
- CABA Nasdaq
- Market Cap
- ATAI 214.8M
- CABA 210.0M
- IPO Year
- ATAI 2021
- CABA 2019
- Fundamental
- Price
- ATAI $1.59
- CABA $2.26
- Analyst Decision
- ATAI Strong Buy
- CABA Strong Buy
- Analyst Count
- ATAI 4
- CABA 10
- Target Price
- ATAI $9.00
- CABA $28.50
- AVG Volume (30 Days)
- ATAI 2.2M
- CABA 1.3M
- Earning Date
- ATAI 11-13-2024
- CABA 11-14-2024
- Dividend Yield
- ATAI N/A
- CABA N/A
- EPS Growth
- ATAI N/A
- CABA N/A
- EPS
- ATAI N/A
- CABA N/A
- Revenue
- ATAI $331,000.00
- CABA N/A
- Revenue This Year
- ATAI $44.72
- CABA N/A
- Revenue Next Year
- ATAI N/A
- CABA N/A
- P/E Ratio
- ATAI N/A
- CABA N/A
- Revenue Growth
- ATAI N/A
- CABA N/A
- 52 Week Low
- ATAI $1.03
- CABA $2.18
- 52 Week High
- ATAI $2.85
- CABA $26.35
- Technical
- Relative Strength Index (RSI)
- ATAI 61.56
- CABA 25.35
- Support Level
- ATAI $1.53
- CABA $4.33
- Resistance Level
- ATAI $1.95
- CABA $4.49
- Average True Range (ATR)
- ATAI 0.20
- CABA 0.40
- MACD
- ATAI 0.04
- CABA -0.20
- Stochastic Oscillator
- ATAI 60.00
- CABA 3.11
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.